Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer
Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology
Dana-Farber Researcher Selected to Join the Pew Scholars Program
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
Staying One Step Ahead
What the Biggest ASCO Cancer Research Updates Could Mean for Patients
Fox Chase Researcher Parth Desai Receives Prestigious ASCO Career Development Award
New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer
ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer
Comprehensive Cancer Care for the Doral Community
RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer
First-in-Human Study Tests Gamitrinib Designed to Disrupt Cancer Cells’ Energy Systems
Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma
Showing 1 - 15 of 1056 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...71 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
